ImmuCell
ICCC
16 hedge funds and large institutions have $5.75M invested in ImmuCell in 2017 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 1 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
39% more capital invested
Capital invested by funds: $4.13M → $5.75M (+$1.62M)
0.77% more ownership
Funds ownership: 15.41% → 16.17% (+0.77%)
0% more funds holding
Funds holding: 16 → 16 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HP
HealthInvest Partners
Stockholm,
Sweden
|
+$82K |
| 2 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
+$62.1K |
| 3 |
PCM
Perritt Capital Management
Chicago,
Illinois
|
+$44.1K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$18.7K |
| 5 |
Renaissance Technologies
New York
|
+$16.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2.84K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
HA
1
Heartland Advisors
Milwaukee,
Wisconsin
| $1.65M | – | – | – |
|
|
HP
2
HealthInvest Partners
Stockholm,
Sweden
| $1.33M | +$82K | +13,810 | +8% |
|
|
PCM
3
Perritt Capital Management
Chicago,
Illinois
| $960K | +$44.1K | +7,427 | +6% |
|
|
4
Renaissance Technologies
New York
| $586K | +$16.6K | +2,800 | +4% |
|
|
SRC
5
Shufro Rose & Co
New York
| $324K | – | – | – |
|
6
Vanguard Group
Malvern,
Pennsylvania
| $250K | – | – | – |
|
|
EFS
7
Essex Financial Services
Essex,
Connecticut
| $174K | – | – | – |
|
8
Wells Fargo
San Francisco,
California
| $169K | – | – | – |
|
|
MA
9
Minerva Advisors
Bala Cynwyd,
Pennsylvania
| $103K | – | – | – |
|
|
EIM
10
Essex Investment Management
Boston,
Massachusetts
| $77K | +$62.1K | +10,462 | New |
|
11
Morgan Stanley
New York
| $54K | – | – | – |
|
|
12
UBS Group
Zurich,
Switzerland
| $41K | +$18.7K | +3,143 | +128% |
|
13
Bank of America
Charlotte,
North Carolina
| $15K | – | – | – |
|
14
BlackRock
New York
| $5K | – | – | – |
|
15
Royal Bank of Canada
Toronto,
Ontario, Canada
| $4K | – | – | – |
|
|
TRCT
16
Tower Research Capital (TRC)
New York
| – | -$2.84K | -478 | -89% |
|
ICCC Hedge Fund Activity: Q2 2017 in Review
16 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in ImmuCell (ICCC) for Q2 2017, worth a combined $5.75M — up 39% from $4.13M a quarter earlier.
Fund positioning in ICCC was balanced in Q2 2017: 1 fund opened new positions, 1 closed out, 4 added to existing stakes and 1 trimmed.
The largest buyer was HealthInvest Partners, adding an estimated $82K. The largest seller was Tower Research Capital (TRC), cutting an estimated $2.84K.
- 16 institutional investors held ImmuCell (ICCC) as of Q2 2017, unchanged from Q1 2017.
- Funds reported $5.75M of ImmuCell stock for Q2 2017, up 39% quarter-over-quarter.
- 1 fund opened new ImmuCell positions in Q2 2017 and 1 closed out, a net change of 0 holders.
- The largest ImmuCell buyer in Q2 2017 was HealthInvest Partners, an estimated $82K added.
- The largest ImmuCell seller in Q2 2017 was Tower Research Capital (TRC), an estimated $2.84K sold.
Based on aggregated 13F filings for Q2 2017.